Abstract
Ublituximab, a Novel, Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), Demonstrates Enhanced Antibody-Dependent Cellular Cytotoxicity (ADCC) Relative to Other Anti-CD20 mAbs (P7-3.011)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have